Table 1

Selected aspects of pharmacokinetics and drug metabolism

CanagliflozinEmpagliflozinDapagliflozinErtugliflozin
Half-life (hours)10.6–13.112.48–12.916.6
Dosing adjustment in patients with impaired renal functioneGFR 45–60 mL/min/1.73 m2, use 100 mg; eGFR <45 mL/min/1.73 m2, do not initiate; contraindicated eGFR <30 mL/min/1.73 m2eGFR <45 mL/min/1.73 m2, do not initiate; contraindicated in severe renal impairment/dialysiseGFR <60 mL/min/1.73 m2, do not initiate; contraindicated eGFR <30 mL/min/1.73 m2eGFR <60 mL/min/1.73 m2, do not initiate; contraindicated eGFR <30 mL/min/1.73 m2
Metabolism: UGT isoformsUGT1A9, UGT2B4UGT2B7, UGT1A3, UGT1A8, UGT1A9UGT1A9UGT1A9, UGT2B7
Metabolism: other pathwaysCYP3A4 (∼7%)Pgp substrate
  • eGFR, estimated glomerular filtration rate; Pgp, permeability glycoprotein.